Keytruda

News

Jemperli cleared for frontline use in endometrial cancer

GSK has claimed US approval for Jemperli alongside chemotherapy for previously untreated, primary advanced or recurrent endometrial cancer, becoming the first immunotherap

News

Study backs earlier use of Keytruda in cervical cancer

A phase 3 trial of Merck & Co’s checkpoint inhibitor Keytruda could support the expansion of its use in cervical cancer to include newly-diagnosed patients with less s

News

EMA starts review of GSK’s Jemperli in endometrial cancer

GSK has moved a step closer to approval of its cancer immunotherapy Jemperli as a first-line treatment for endometrial cancer in the EU.

News

Phase 3 setbacks mar Eisai, Merck’s cancer alliance

Two late-stage trials combining Merck & Co’s cancer immunotherapy Keytruda with Eisai’s targeted cancer drug Lenvima have generated disappointing results in hard-to-tr

News

FDA clears Keytruda/Padcev regimen for bladder cancer

The combination of Merck & Co’s checkpoint inhibitor Keytruda and Seagen/Astellas’ antibody-drug conjugate Padcev has been approved by the FDA as an alternative to che

News

GSK, Merck in endometrial cancer face-off

GSK and Merck & Co have both reported new clinical data with the PD-1 checkpoint inhibitors, seeking an edge in the first-line treatment of advanced endometrial cancer

Jemperli cleared for frontline use in endometrial cancer

Study backs earlier use of Keytruda in cervical cancer

EMA starts review of GSK’s Jemperli in endometrial cancer

Phase 3 setbacks mar Eisai, Merck’s cancer alliance

FDA clears Keytruda/Padcev regimen for bladder cancer

GSK, Merck in endometrial cancer face-off

NHS use of digital cardiac rehab tools endorsed

How to meet your physicians where they are online

Keytruda

Editor's Picks